41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLC

Empowered Funds LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 41,426 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,498,000. Empowered Funds LLC owned about 0.08% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Stephens Investment Management Group LLC lifted its stake in Supernus Pharmaceuticals by 1.8% during the third quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares during the last quarter. Pacer Advisors Inc. increased its position in Supernus Pharmaceuticals by 29.9% in the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after buying an additional 403,028 shares during the period. Geode Capital Management LLC increased its position in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after buying an additional 74,438 shares during the period. Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after buying an additional 7,833 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Supernus Pharmaceuticals by 14.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after buying an additional 91,354 shares during the period.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald initiated coverage on Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $39.11 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The business’s fifty day moving average price is $37.54 and its two-hundred day moving average price is $35.10. The firm has a market capitalization of $2.16 billion, a PE ratio of 36.55 and a beta of 0.90.

Insider Activity

In other news, VP Padmanabh P. Bhatt sold 700 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This trade represents a 6.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.